Introduction
============

Non-alcoholic fatty liver disease (NAFLD) is a pandemic disease, and one-third of the population worldwide is affected ([@b1-mmr-18-02-2033],[@b2-mmr-18-02-2033]). Since the liver is one of the target organs of insulin, a high prevalence of insulin resistance is seen in patients with NAFLD ([@b3-mmr-18-02-2033],[@b4-mmr-18-02-2033]). An increase in insulin resistance is associated with the development of not only type 2 diabetes mellitus but also life-threatening diseases such as liver cirrhosis, hepatocellular carcinoma, and cardiovascular diseases in patients with NAFLD ([@b5-mmr-18-02-2033]). Thus, improved insulin resistance is an important therapeutic target in patients with NAFLD. Anti-diabetic agents including pioglitazone ([@b6-mmr-18-02-2033]), glucagon-like peptide-1 (GLP-1) analogue ([@b7-mmr-18-02-2033]), and sodium-glucose cotransporter 2 inhibitor ([@b8-mmr-18-02-2033]) lead to metabolic and histologic improvement in patients with NAFLD complicated by diabetes mellitus. However, no effective medication has been approved yet for patients with NAFLD.

Isomaltulose (6-0-α-D-glucopyranosyl-D-fructose) is a naturally-occurring disaccharide found in honey ([@b9-mmr-18-02-2033]) and is composed of glucose and fructose, similar to sucrose ([@b10-mmr-18-02-2033]). Both isomaltulose and sucrose are digested into glucose and fructose by α-glucosidase in the small intestine and contribute the same caloric value of 4 kcal/g ([@b11-mmr-18-02-2033],[@b12-mmr-18-02-2033]). However, the digestive rate of isomaltulose is significantly slower than that of sucrose because the structural feature of isomaltulose is that glucose and fructose are linked by an alpha-1,6-glycosidic bond ([@b12-mmr-18-02-2033],[@b13-mmr-18-02-2033]). In addition, isomaltulose affects the secretion of gut hormones such as glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 ([@b14-mmr-18-02-2033],[@b15-mmr-18-02-2033]), leading to an improvement of insulin resistance. Thus, isomaltulose is a low glycemic index sweetener as well as a functional disaccharide and is currently used in various medical food and drink applications instead of sucrose ([@b16-mmr-18-02-2033]).

In a rat model of metabolic syndrome, isomaltulose is reported to reduce visceral fat mass and improves glucose intolerance, resulting in inhibition of increase in blood pressure and progression of diabetic nephropathy ([@b17-mmr-18-02-2033]). Furthermore, in healthy subjects, isomaltulose ingestion inhibits an increase in insulin resistance and blood pressure ([@b11-mmr-18-02-2033],[@b18-mmr-18-02-2033]). The beneficial effects of isomaltulose on visceral fat, insulin resistance, and blood pressure in patients who were obese have been reported in double-blind, placebo-controlled interventional studies ([@b19-mmr-18-02-2033],[@b20-mmr-18-02-2033]). However, the effect of isomaltulose on insulin resistance has never been investigated in patients with NAFLD.

An increase in insulin resistance can be caused by various factors including amino acid, fatty acid, and bile acid metabolism ([@b3-mmr-18-02-2033],[@b21-mmr-18-02-2033],[@b22-mmr-18-02-2033]). Metabolomic analysis is a systematic examination of metabolites in a given biological sample and can reveal novel pathways ([@b23-mmr-18-02-2033]). Metabolomic analysis has recently been applied to the identification of the pharmacological mechanisms of berberine, an isoquinoline alkaloid, for nonalcoholic steatohepatitis (NASH) treatment and revealed metabolic disruption involving phospholipids and unsaturated fatty acids in a rat model of NASH ([@b24-mmr-18-02-2033]). However, metabolomic analysis has not been used to identify the pharmacological mechanisms of isomaltulose in patients with NAFLD.

The aim of this study was to investigate effects of isomaltulose on insulin resistance in patients with NAFLD. In addition, using metabolomic analysis, we investigated the effect of isomaltulose on various metabolisms in patients with NAFLD.

Subjects and methods
====================

### Study design and ethics

This was a randomized, single-blinded controlled interventional study, and our study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki, as reflected by the prior approval of the institutional review board of The Ethic Committee of Kurume University. All experiments were performed in accordance with relevant guidelines and regulations. All subjects provided written informed consent to participate in this study.

### Subjects

A total of 5 male patients diagnosed with NAFLD were enrolled in this study. The following patient inclusion criteria were used: Patients with i) NAFLD, ii) age \>20 years, and iii) written informed consent. The exclusion criteria were as follows: Patients with i) hemoglobin A1c \>8.0%, ii) insulin or α-glucosidase inhibitor treatment, iii) liver cirrhosis, iv) renal failure, v) a history of cardiovascular disease, or vi) participation in any other clinical trial.

The subjects were randomly assigned into the sucrose (Control) or isomaltulose group. After a 14-day wash-out term, each subject was assigned to the other group.

### Diagnosis of NAFLD

NAFLD was diagnosed according to the Clinical Practice Guidelines for NAFLD/NASH as follows ([@b25-mmr-18-02-2033]): i) hepatic steatosis evaluated by liver biopsy, ultrasonography, computed tomography, or magnetic resonance imaging; ii) ethanol intake \<30 g/day; and iii) exclusion of other liver diseases, including chronic hepatitis B, chronic hepatitis C, autoimmune hepatitis, drug-induced liver disease, primary biliary cholangitis, primary sclerosing cholangitis, biliary obstruction, Wilson\'s disease, and hemochromatosis.

### Isomaltulose or sucrose administration and blood collection

After a 12-hour overnight fast, the subjects consumed 20 g isomaltulose in 200 ml of water or 20 g sucrose (Control) in 200 ml of water in 1 min at 8:30 a.m. During the procedure, the subjects were instructed to rest on a bed and fast. Venous blood samples were collected before and 15 min after administration. For plasma GIP and GLP-1 measurements, blood samples were collected into a BD™ P100 Blood Collection System containing protein stabilizers (BD Biosciences, Franklin Lakes, NJ, USA). Blood samples were centrifuged at 3,000 × g for 15 min at 4°C and stored at −20°C until analysis.

### Laboratory determinations

Serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH), γ-glutamyl transpeptidase (GGT), total bilirubin, total cholesterol, low-density lipoprotein (LDL)-cholesterol, blood urea nitrogen (BUN), creatinine, nonesterified fatty acid, C-peptide immunoreactivity (CPR), and blood glucose level were measured using standard clinical methods (SRL Inc., Tokyo, Japan) as previously described ([@b4-mmr-18-02-2033],[@b26-mmr-18-02-2033],[@b27-mmr-18-02-2033]).

### Measurement of serum GIP and GLP-1 levels

As previously described ([@b28-mmr-18-02-2033]), plasma GIP and GLP-1 levels were measured by an enzyme-linked immunosorbent assay using a Human GIP ELISA kit (YK253; Yanaihara Institute Inc., Fujimiya, Japan) and a Human GLP1 ([@b7-mmr-18-02-2033]--[@b36-mmr-18-02-2033]) ELISA kit (ab184857; Abcam, Cambridge, UK), respectively, according to each manufacturer\'s instructions.

### Metabolomic analysis

Metabolomic analysis was performed twice using serum samples taken before (0 min) and 15 min after isomaltulose or sucrose treatment.

### Preparation

Serum samples taken before and 15 min after isomaltulose or sucrose treatment from a representative subject were applied to a metabolomic analysis. Metabolome measurements were performed at a service facility of LSI Medience Corporation (Tokyo, Japan). Briefly, serum (200 µl) was added to methanol (800 µl) and then mixed for 15 min with a shaker at room temperature. After it was centrifuged by 10,000 × g for 10 min, the supernatant was dried up with nitrogen gas, and the residue was dissolved with 10% acetonitrile aqueous solution (200 µl). After adding internal standards, they were analyzed with both liquid chromatography mass spectrometry (LC-MS) and capillary electrophoresis coupled to mass spectrometry (CE-MS). Tuning and calibration were performed with a standard solution provided by Agilent Technology, and the resolution errors were controlled within 3 ppm. The order of measurement was randomized to minimize the specific error in each group. Quality control samples were prepared by pooling samples and were analyzed every 5 samples to verify the measurement accuracy.

### LC-time-of-flight mass spectrometry (TOFMS) analysis

LC-MS datasets were acquired on a liquid chromatography system (Agilent HP1200; Agilent Technologies, Inc., Santa Clara, CA, USA) equipped with a C18 column (2 µm, 50×2.0 mm ID, CAPCELL PAK C18 IF; Shiseido, Tokyo, Japan) and coupled with an electrospray ionization quadrupole TOFMS (Agilent 6520; Agilent Technologies, Inc.). Solvent A was composed of a 5 mM ammonium acetate aqueous solution, while solvent B was acetonitrile. Metabolites were eluted at a flow rate of 0.2 ml/min at 40°C with a linear gradient of 10--90% solvent B over 10 min, followed by a further 5 min hold at 100% solvent B. The mass spectrometer was operated in positive and negative scan mode (m/z 60 to 1,200) with a capillary voltage of 3,500 V. The nebulizing gas pressure was 40 psi, and the dry gas flow was 8 l/min at 350°C.

### CE-TOFMS analysis

Ionic metabolites were measured in the positive mode of CE-TOFMS (Agilent CE-TOFMS 6520; Agilent Technologies, Inc.,). Metabolites were separated in a fused-silica capillary (50 µm i.d.x100 cm total length; GL Science, Tokyo, Japan) filled with 1 mol/l formic acid aqueous solution (cation mode), or 20 mM ammonium formate and 20 mM ammonium acetate aqueous solution (pH 10, anion mode) as an electrolyte. The sample solution was injected at 5 kPa for 15 sec (approximately 15 nl), and a voltage of 30 kV was applied. The temperatures of capillary and sample trays were maintained at room temperature and 5°C, respectively. The sheath liquid was methanol/water (50%v/v) containing 5 mM ammonium acetate. CE-TOFMS was operated in both positive and negative scan mode (m/z 60 to 1,200). The capillary voltage was set at 3,500 V, and the nitrogen gas (heater temperature 250°C) flow rate was set at 10 l/min.

### Data analysis

A data file of mass spectrometry was converted to csv format with an Agilent csv converter. All peak positions (retention time and m/z) and areas were calculated by Markeranalysis (LSI Medience, Tokyo, Japan) ([@b29-mmr-18-02-2033]). All peak areas were aligned into one data sheet, and the errors of peak intensities were corrected by internal standards. Noise peaks were deleted compared with the peaks detected in blank samples. Metabolites were identified by comparing the retention time and m/z with standard data set established by LSI Medience Corporation.

### Effects of isomaltulose on insulin resistance, GIP, GLP-1 secretion, and metabolites

Insulin resistance was evaluated by an increment of serum CPR as previously described ([@b30-mmr-18-02-2033]). ΔCPR was the change of serum CPR level from baseline to 15 min after sucrose or isomaltulose administration. Similarly, changes in GIP and GLP-1 secretions were evaluated by ΔGIP and ΔGLP-1, which were changes of plasma GIP and GLP-1 levels from baseline to 15 min after sucrose or isomaltulose administration, respectively. The effects of isomaltulose on metabolites were also evaluated by change of each metabolite level from baseline (0 min) to 15 min after sucrose or isomaltulose administration (Δ each metabolite). Variable that increased or decreased after the administration was shown as positive or negative expression level (∆ variable or -∆ variable) ([Fig. 1](#f1-mmr-18-02-2033){ref-type="fig"}).

### Statistical analysis

Data are expressed as numbers or means ± standard deviations. Differences between the two groups were analyzed using the Wilcoxon signed-rank test. In metabolome analysis, mea n fold-change and t-test for all detected peaks were performed between the two groups. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Baseline patient characteristics

The baseline patient characteristics are summarized in [Table I](#tI-mmr-18-02-2033){ref-type="table"}. No significant difference was seen in the serum levels of AST, ALT, GGT, or total bilirubin between the sucrose (Control) and Isomaltulose groups. There was no significant difference in fasting blood glucose or serum CPR levels between the 2 groups ([Table I](#tI-mmr-18-02-2033){ref-type="table"}).

### Effect of isomaltulose on changes in blood glucose and serum CPR levels

The effect of isomaltulose on blood glucose and serum CPR levels was evaluated by changes in these variables from baseline to 15 min after sucrose or isomaltulose administration. Although there was no significant difference in changes of blood glucose levels, the serum CPR level was significantly decreased in the Isomaltulose group compared to that in the Control group ([Fig. 2](#f2-mmr-18-02-2033){ref-type="fig"}).

### Effect of isomaltulose on changes in plasma GIP and GLP-1 levels

The effect of isomaltulose on plasma GIP and GLP-1 levels was evaluated by changes in these variables from baseline to 15 min after sucrose or isomaltulose administration. There was no significant difference in changes of plasma GIP and GLP-1 levels between the Control and Isomaltulose groups ([Table II](#tII-mmr-18-02-2033){ref-type="table"}).

### Effect of isomaltulose on serum metabolite levels

With metabolomic analysis, the effects of isomaltulose on 201 metabolite levels were evaluated by changes in these variables from baseline to 15 min after sucrose or isomaltulose administration. A significant alteration was seen in 52 metabolites between the Control and Isomaltulose groups ([Table III](#tIII-mmr-18-02-2033){ref-type="table"}). Many of these 52 altered metabolites were categorized as bile acid (6 metabolites), fatty acid (6 metabolites), or glycine/serine metabolism (4 metabolites) ([Fig. 3](#f3-mmr-18-02-2033){ref-type="fig"}).

A representative change of metabolite in each category was an increased taurodeoxycholic acid level in the bile acid category, a decreased arachidonic acid level in the fatty acid category, and an increased betaine level in the glycine/serine category after isomaltulose treatment ([Fig. 4A-C](#f4-mmr-18-02-2033){ref-type="fig"}). In addition, a significant decrease was seen in the serum L-arginine level in the isomaltulose group compared to that in the Control group ([Fig. 4D](#f4-mmr-18-02-2033){ref-type="fig"}), while the serum L-ornithine level was significantly increased in the isomaltulose group compared to that in the Control group ([Fig. 4E](#f4-mmr-18-02-2033){ref-type="fig"}).

Discussion
==========

In this study, we demonstrated that isomaltulose improved insulin resistance in patients with NAFLD. Although isomaltulose did not have a significant effect on the changes in serum GIP and GLP-1 levels, we showed that isomaltulose significantly affects various metabolites, in particular, taurodeoxycholic acid, arachidonic acid, and betaine. Thus, isomaltulose may have a beneficial effect on insulin resistance through alterations in various metabolisms, in particular bile acid, fatty acid, and glycine/serine metabolisms.

Isomaltulose has been reported to improve insulin resistance in rats and in patients who are obese ([@b19-mmr-18-02-2033],[@b31-mmr-18-02-2033]). In agreement with these previous reports, the serum CPR level was significantly decreased in the Isomaltulose group compared to that in the Control group in this study. Thus, we demonstrated that isomaltulose improved insulin resistance in patients with NAFLD. In this study, serum CPR was used for evaluation of insulin resistance instead of immunoreactive insulin (IRI). This was because DCPR is the most significant determinant of insulin secretion increments ([@b30-mmr-18-02-2033]). Moreover, in patients with chronic liver disease, the hepatic insulin degradation rate is decreased, and CPR is more accurate than IRI for the evaluation of insulin secretion ([@b32-mmr-18-02-2033]). Furthermore, the IRI level is affected by hemolysis during blood collection ([@b33-mmr-18-02-2033]) and is inaccurate in the presence of an anti-insulin antibody ([@b34-mmr-18-02-2033]).

The slow digestive rate of isomaltulose is reported to affect secretion of GIP and GLP-1, resulting in a reduction of insulin resistance ([@b14-mmr-18-02-2033],[@b15-mmr-18-02-2033]). However, in this study, no significant change was seen in GIP or GLP-1 levels. The reason for the discrepancy between previous studies and our study remains unclear, and following are possible explanations ([@b1-mmr-18-02-2033]): The number of enrolled patients may not have had enough power to detect significant changes or ([@b2-mmr-18-02-2033]) since plasma dipeptidyl peptidase-4 activity is accelerated in patients with NAFLD ([@b35-mmr-18-02-2033]), degradation of GIP and GLP-1 could be increased in patients with NAFLD.

To investigate possible mechanisms for isomaltulose-induced suppression of insulin resistance, we performed a metabolomic analysis and demonstrated that isomaltulose had significant effects on various metabolites in patients with NAFLD. A large number of altered metabolites were categorized into bile acid, fatty acid, or glycine/serine metabolisms. A representative change in each category was an increased taurodeoxycholic acid level, a decreased arachidonic acid level, and an increased betaine level in bile acid, fatty acid, and glycine/serine metabolisms, respectively. The causal relationships between these changes in metabolites and the improvement of insulin resistance remain unclear. However, Qi *et al* reported that taurodeoxycholic acid may reduce the increase of phospholipids, sphingomyelins, and ceramides induced by a high-fat diet, leading to an improvement of insulin resistance in a mouse model ([@b36-mmr-18-02-2033]). Arachidonic acid is reported to down-regulate the insulin-dependent glucose transporter gene, resulting in an increase in insulin resistance ([@b37-mmr-18-02-2033]). In addition, betaine was recently reported to improve insulin resistance through an activation of forkhead box O1-induced NLRP3 inflammasomes ([@b38-mmr-18-02-2033]). These previous reports support that isomaltulose may have improved insulin resistance potentially through alterations in bile acid, fatty acid, and glycine/serine metabolisms in this study.

The metabolomic analysis also revealed a significant decrease in the serum L-arginine level and a significant increase in the serum L-ornithine level in the isomaltulose group. L-arginine is reported to inhibit gene expression of insulin receptor substrate-1, phosphatidylinositol 3-kinase, and Akt in the insulin signaling pathway, leading to an increase in insulin resistance ([@b39-mmr-18-02-2033]). L-ornithine is reported to regulate growth hormone/insulin-like growth factor-1/insulin-like growth factor-binding protein 3 complex in muscle tissue, leading to improved insulin resistance ([@b40-mmr-18-02-2033]). Taken together, along with alterations in bile acid, fatty acid, and glycine/serine metabolisms, alterations in L-arginine and L-ornithine may contribute to improvement of insulin resistance in patients with NAFLD.

A major limitation of this study is small sample size, and further study is required to verify of our results. In this study, changes in metabolisms were evaluated by a global metabolomic analysis. Since environmental factors including outdoor temperature are known to be associated with insulin resistance and other metabolisms ([@b41-mmr-18-02-2033]--[@b43-mmr-18-02-2033]), isomaltulose or sucrose was administered to the all subjects at the same time on the same day by personal stuffs. Thus, sample size was limited because of the equalization for environmental factors in this study. Another limitation is that taste of isomaltulose is slightly different from that of sucrose and subjects might recognize the difference between isomaltulose and sucrose. However, taste correlates with chemical structure ([@b44-mmr-18-02-2033],[@b45-mmr-18-02-2033]), and it is impossible to have a control disaccharide with same taste of isomaltulose. In this study, a random assignment was performed just before the administration and then, subjects were at rest on a bed and fast during the procedure. Thus, the taste difference between isomaltulose and sucrose is considered to have no influence on the results.

In conclusion, we showed that isomaltulose improved insulin resistance in patients with NAFLD. In addition, we revealed that isomaltulose significantly affect various metabolites, including taurodeoxycholic acid, arachidonic acid, and betaine. Thus, isomaltulose may improve insulin resistance mainly through alterations in various metabolisms in patients with NAFLD.
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![Effect of isomaltulose on changes in blood glucose and serum CPR levels. The effect of isomaltulose on blood glucose (A) and serum CPR levels (B) was evaluated by changes in these variables from baseline to 15 min after sucrose (Control) or isomaltulose administration. P-values of \<0.05 were considered significant. N.S., not significant; CPR, C-peptide immunoreactivity.](MMR-18-02-2033-g01){#f2-mmr-18-02-2033}
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![Effect of isomaltulose on serum taurodeoxycholic acid, arachidonic acid, betaine, L-arginine, and L-ornithine levels. The effect of isomaltulose on serum (A) taurodeoxycholic acid, (B) arachidonic acid, (C) betaine, (D) L-arginine, and (E) L-ornithine levels was evaluated by changes in these variables from baseline (0 min) to 15 min after sucrose (Control) or isomaltulose administration. P-values of \<0.05 were considered significant.](MMR-18-02-2033-g03){#f4-mmr-18-02-2033}

###### 

Patients\' characteristics at baseline.

  Characteristic                                Control       Isomaltulose   P-value
  --------------------------------------------- ------------- -------------- ---------
  Age (yeare)                                   48.6±11.8     48.6±11.8      1.0000
  Body mass index                               35.1±7.0      35.1±7.0       1.0000
  Red blood cells (×10^4^/µl)                   509.6±70.6    514.4±59.7     0.9105
  Hemoglobin (g/dl)                             15.5±1.8      15.6±1.3       0.9540
  White blood cells (/µl)                       8,500±2,515   7,600±2,531    0.5882
  Platelet count (×10^4^/µl)                    29.5±4.1      28.7±4.2       0.7634
  Aspartate aminotransferase (IU/l)             31.2±13.2     30.0±14.7      0.8953
  Alanine aminotransferase (IU/l)               45.6±36.9     40.2±28.5      0.8024
  Lactate dehydrogenase (IU/l)                  227.2±109.8   237.2±108.4    0.8884
  γ-glutamyl transpeptidase (IU/l)              55.6±39.9     54.4±36.0      0.9614
  Total bilirubin (mg/dl)                       0.52±0.18     0.46±0.18      0.6130
  Total cholesterol (mg/dl)                     207.0±26.4    197.2±21.1     0.5350
  Low-density lipoprotein cholesterol (mg/dl)   138.6±17.6    125.0±23.8     0.3362
  Triglycerides (mg/dl)                         144.2±51.4    154.2±56.5     0.7772
  Blood urea nitrogen (mg/dl)                   14.7±2.9      14.7±4.2       0.9864
  Creatinine (mg/dl)                            0.85±0.16     0.80±0.20      0.6998
  Fasting blood glucose (mg/dl)                 132.0±38.7    145.0±50.0     0.6586
  C-peptide immunoreactivity (ng/dl)            2.38±0.99     2.61±1.71      0.8025
  Nonesterified fatty acid (µEq/l)              675.0±316.8   574.4±221.0    0.5782

Data are expressed as mean ± SD. Differences between the two groups were analyzed using Wilcoxon signed-rank test. P-values of \<0.05 are considered significant.

###### 

Effects of isomaltulose on changes in plasma GIP and GLP-1 levels.

  Level    Control      Isomaltulose   P-value
  -------- ------------ -------------- ---------
  ∆GIP     23.1±25.6    14.0±9.5       0.8345
  ∆GLP-1   −51.5±98.0   166.7±66.6     0.1437

Data are expressed as mean ± SD. ∆GIP and ∆GLP-1 are changes of plasma GIP and GLP-1 levels from baseline to 15 min after sucrose (Control) or isomaltulose administration, respectively. Differences between the 2 groups were analyzed using the Wilcoxon signed-rank test. P-values of \<0.05 are considered significant. GIP, glucose-dependent insulinotropic polypeptide; GLP-1, glucagon-like peptide-1.

###### 

Metabolites significantly altered by isomaltulose in patients with NAFLD.

                                                                                         Control   Isomaltulose                              
  ----- ------------------------------------ ------------------------------------------- --------- -------------- -------- -------- -------- --------
    1   L-Arginine                           Amino acid                                  −507      80             −2,570   180      5.00     0.0001
    2   L-Ornithine                          Urea cycle                                  −62       64             1,390    137      −25.00   0.0001
    3   N-Acetylornithine                    Arginin, proline metabolism                 −60       157            −1,832   111      33.33    0.0001
    4   Glycodeoxycholate                    Bile acid                                   29        3              134      12       4.55     0.0001
    5   Urea                                 Urea cycle                                  −79       12             115      23       −1.45    0.0002
    6   Betaine                              Glycine, serin metabolism                   −446      398            2,613    307      −5.88    0.0005
    7   D-Xylulose                           Sugar                                       51        6              88       2        1.72     0.0006
    8   Glycocholate                         Bile acid                                   1,423     93             25,816   1,114    16.67    0.0006
    9   6-Aminohexanoate                     Fatty acid metabolism                       14        3              42       5        2.94     0.0008
  10    Indole acetate                       Tryptophan metabolism                       −170      25             41       32       −0.24    0.0008
  11    Theobromine                          Caffeine metabolism                         −440      139            350      80       −0.79    0.0010
  12    Taurodeoxycholic acid                Bile acid                                   2,848     49             36,895   1,997    12.50    0.0011
  13    Uridine                              Pyrimidine metabolism                       416       135            1,917    323      4.55     0.0017
  14    L-Lactic acid                        Glycolysis                                  5,159     744            2,058    178      0.40     0.0022
  15    Eicosadienoic acid (20:2)            Fatty acid                                  −18,121   2,263          2,174    4,642    −0.12    0.0024
  16    D-Glycerate                          Glycine, serin metabolism                   3         11             239      60       100.00   0.0026
  17    1-6-Anhydro-beta-d-Glucose           Sugar metabolism                            642       39             1,409    202      2.17     0.0030
  18    N-N-dimethylarginine                 Arginin, proline metabolism                 −19       20             102      26       −5.26    0.0032
  19    Tridecanoic acid                     Fatty acid                                  51        76             719      181      14.29    0.0041
  20    Taurocholate                         Bile acid                                   16        23             210      54       12.50    0.0046
  21    Creatinine                           Arginin, proline metabolism                 −994      580            1,401    494      −1.41    0.0055
  22    Choline                              Glycine, serin metabolism                   −2,423    443            1,316    1,183    −0.54    0.0069
  23    Gramine                              Tryptophan metabolism                       15        20             −136     47       −9.09    0.0070
  24    5-Oxoproline                         Glutathione metabolism                      −77       41             523      213      −6.67    0.0087
  25    Pseudouridine                        Pyrimidine metabolism                       51        37             −59      20       −1.15    0.0103
  26    Eicosenoic acid (20:1)               Fatty acid                                  18,075    4,264          −2,476   6,533    −0.14    0.0103
  27    (R)-3-Hydroxybutanoate               Butanoate metabolism                        13        62             190      30       14.29    0.0113
  28    Taurocyamine                         Taurine and hypotaurine metabolism          −233      112            153      103      −0.66    0.0118
  29    Hydroxypropionic acid                Pyrimidine metabolism                       −59       23             −137     22       2.33     0.0131
  30    D-Glyceraldehyde                     Sugar metabolism                            14,027    292            4,661    2,058    0.33     0.0143
  31    Docosapentaenoate (n3 DPA; 22:5n3)   Fatty acid                                  −14,387   2,318          10,570   10,482   −0.74    0.0158
  32    4-Methyl-2-oxopentanoate             Valine, leucine and isoleucine metabolism   72        70             252      39       3.45     0.0178
  33    Hyodeoxycholate                      Bile acid                                   332       83             128      37       0.38     0.0179
  34    L-Histidine                          Amino acid                                  −41       49             215      104      −5.26    0.0183
  35    L-Methionine S-oxide                 Cystein metabolism                          19        12             −19      12       −1.02    0.0190
  36    Undecanoate (11:0)                   Fatty acid                                  −22       62             343      155      −16.67   0.0191
  37    beta-D-Glucose                       Sugar                                       2,496     550            3,920    372      1.56     0.0206
  38    Abscisate                            Plant metabolites                           −4        17             36       9        −10.00   0.0216
  39    N2,N2-Dimethylguanosine              Nucleotide metabolism                       −75       33             13       25       −0.18    0.0218
  40    1-5-anhydro-D-glucitol               Sugar                                       −2        8              15       2        −7.69    0.0223
  41    1-Methylhistidine                    Histidine metabolism                        −132      123            255      148      −1.92    0.0250
  42    beta-hydroxyisovaleric acid          Valine, leucine and isoleucine metabolism   −254      130            508      355      −2.00    0.0251
  43    Arachidonate                         Fatty acid                                  48,499    15,330         −473     20,184   −0.01    0.0287
  44    N,N-Dimethylglycine                  Glycine, serin metabolism                   −23       21             127      75       −5.56    0.0290
  45    (±)-1,2-Diphenylethylenediamine      Unclassified                                26        18             −53      37       −2.04    0.0301
  46    Caffeine                             Caffeine metabolism                         −1,724    485            110      895      −0.06    0.0355
  47    α-D-Glucose 6-phosphate              Glycolysis                                  2         43             122      52       50.00    0.0364
  48    (S)(+)-Allantoin                     Purine metabolism                           955       82             718      109      0.75     0.0398
  49    Chenodeoxycholate                    Bile acid                                   3,201     854            1,629    332      0.51     0.0411
  50    Homogentisate                        Phenylalanine tyrosine metabolism           −54       39             33       34       −0.62    0.0424
  51    Ranitidine                           Unclassified                                6         10             −14      6        −2.17    0.0432
  52    L-Tryptophan                         Amino acid                                  −144      45             282      255      −1.96    0.0463

SD, standard deviation.
